Table 2.
Blood test, pulmonary, and cardiac function of 90 long-term survivors of allo-HSCT according to chemotherapy prior to HSCT (no/yes)
| All | No | Yes | p value | BOS* | |
|---|---|---|---|---|---|
| Pulmonary function | n = 90 | n = 46 (51%) | n = 33 (37%) | n = 11 (12%) | |
| TLC % predicted | 104 (101–106) | 105 (101–108) | 103 (98–107) | 0.71 | 105 (98–112) |
| RV % predicted | 117 (112–123) | 115 (108–122) | 120 (111–129) | 0.89 | 157 (145–170) |
| FVC % predicted | 93 (90–96) | 96 (92–100) | 90 (86–95) | 0.36 | 80 (73–87) |
| FEV1% predicted | 88 (84–92) | 92 (87–97) | 84 (78–90) | 0.17 | 56 (46–66) |
| FEV1/FVC | 0.78 (0.75–0.80) | 0.79 (0.76–0.83) | 0.76 (0.73–0.79) | 0.19 | 0.58 (0.50–0.66) |
| DLCO % predicted | 83 (80–87) | 87 (83–92) | 79 (75–84) | 0.02 | 85 (74–95) |
| Cardiac function | n = 49 (54%) | n = 41 (46%) | |||
| LVEF (%) | 55 (54–56) | 57 (55–58) | 54 (51–56) | 0.01 | |
| Left ventricular dysfunction | 28 (31%) | 6 (25%) | 22 (33%) | 0.02 | |
| Hypercholesterolemia | 15 (17%) | 1 (5%) | 14 (25%) | 0.51 | |
| Hypertension | 37 (41%) | 6 (27%) | 31 (54%) | 0.18 | |
| Blood analysis | |||||
| proBNP, pmol/L† | 5.5 (0.7–79.0) | 3.9 (0.7–19.0) | 9.0 (1.4–79.0) | < 0.001 | |
| CRP, mg/L† | 1.5 (0.6–14.0) | 1.2 (0.6–14.0) | 1.7 (0.6–12.0) | 0.11 | |
| Hb, g/dl | 14.3 (14.1–14.6) | 14.3 (14–14.7) | 14.3 (13.8–14.7) | 0.78 | |
| HbA1c† | 5.4 (4.2–6.7) | 5.3 (5.2–5.4) | 5.4 (5.3–5.6) | 0.13 | |
*BOS patients were separated in a column for the pulmonary function values. HSCT, hematopoietic stem cell transplantation; BOS, bronchiolitis obliterans syndrome; TLC, total lung capacity; RV, residual volume; FVC, forced vital capacity; FEV1, forced expiratory volume-one second; DLCO, diffusing capacity for carbon monoxide; LVEF, left ventricular ejection fraction; proBNP, pro B-type natriuretic peptide; CRP, C-reactive protein; Hb, hemoglobin concentration; HbA1c, glycated hemoglobin. Data are presented as mean (95% confidence interval), number (%) or † median (range)